Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 18,000 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 18,000 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $181.09, for a total transaction of $3,259,620.00. Following the sale, the director directly owned 390,826 shares in the company, valued at $70,774,680.34. The trade was a 4.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock traded down $0.34 during trading hours on Thursday, reaching $175.74. The company had a trading volume of 1,664,525 shares, compared to its average volume of 947,213. The firm has a market cap of $10.68 billion, a PE ratio of -26.11, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $182.99. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The business has a fifty day simple moving average of $137.84 and a 200 day simple moving average of $121.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.87 by $2.26. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same period in the previous year, the company posted $6.54 EPS. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on JAZZ. JPMorgan Chase & Co. cut their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday, October 27th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Royal Bank Of Canada set a $194.00 price target on shares of Jazz Pharmaceuticals and gave the company an “outperform” rating in a report on Monday. Truist Financial raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Finally, The Goldman Sachs Group raised their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a report on Friday, August 29th. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $195.07.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Faithward Advisors LLC increased its position in Jazz Pharmaceuticals by 93.4% during the third quarter. Faithward Advisors LLC now owns 27,904 shares of the specialty pharmaceutical company’s stock valued at $3,678,000 after acquiring an additional 13,475 shares during the last quarter. Sunbelt Securities Inc. bought a new stake in Jazz Pharmaceuticals during the third quarter valued at approximately $53,000. Coldstream Capital Management Inc. boosted its stake in shares of Jazz Pharmaceuticals by 36.5% during the 3rd quarter. Coldstream Capital Management Inc. now owns 4,472 shares of the specialty pharmaceutical company’s stock worth $589,000 after acquiring an additional 1,195 shares during the last quarter. Danske Bank A S purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter worth approximately $40,000. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Jazz Pharmaceuticals by 1,383.3% in the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 332 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.